Bone Reports
Volume 2, 2015, Pages 82-88

Effect of vitamin D3-supplementation on bone markers (serum P1NP and CTX): A randomized, double blinded, placebo controlled trial among healthy immigrants living in Norway (Article) (Open Access)

Madar A.A.* , Knutsen K.V. , Stene L.C. , Brekke M. , Lagerløv P. , Meyer H.E. , Macdonald H.M.
  • a Department of Community Medicine, Institute of Health and Society, University of Oslo, Norway
  • b Department of General Practice, Institute of Health and Society, University of Oslo, Norway
  • c Division of Epidemiology, Norwegian Institute of Public Health, Oslo, Norway
  • d Department of General Practice, Institute of Health and Society, University of Oslo, Norway
  • e Department of General Practice, Institute of Health and Society, University of Oslo, Norway
  • f Department of Community Medicine, Institute of Health and Society, University of Oslo, Norway, Division of Epidemiology, Norwegian Institute of Public Health, Oslo, Norway
  • g School of Medicine and Dentistry, University of Aberdeen, Aberdeen, United Kingdom

Abstract

Objective: Vitamin D is essential for the maintenance of calcium homeostasis and bone mineralization; and low serum 25-hydroxyvitamin D (s-25-(OH)D) concentrations are associated with increased bone turnover. However, there is a lack of randomized controlled trials that have investigated the effect of vitamin D treatment on bone turnover in immigrant populations. We aimed to investigate the effect of 16-week daily vitamin D3 supplementation on bone formation marker serum procollagen type 1 amino-terminal propeptide (P1NP) and bone resorption marker C-terminal crosslinked telopeptide of type I collagen (CTX). Design: Double-blind, randomized, placebo-controlled trial. Setting: Immigrant community centers in Oslo, Norway. Participants: 251 healthy adults aged 18-50. years with a non-Western immigrant background were recruited. Intervention: 16weeks of daily oral supplementation with either 10μg vitamin D3, 25μg vitamin D3, or placebo. Main outcome measures: Difference in change during the 16-week intervention between the intervention groups combined (10 or 25μg of vitamin D3/day) and placebo, in serum P1NP and serum CTX. Results: A total of 214 (85%) participants completed the study. S-25-(OH)D increased from 29nmol/L at baseline to 49nmol/L in the intervention group with no significant change in the placebo group. However, there was no difference in change of serum P1NP (mean difference: -1.2μg/L (95% CI: -5.4, 2.9, P=0.6)) and serum CTX (mean difference: -0.005μg/L (95% CI: -0.03, 0.02, P=0.7)) between those receiving vitamin D3 supplementation compared with placebo. The plasma PTH had decreased by a mean of -1.97pmol/L (95% CI: -2.7, -1.3, P<0.0001) in the vitamin D3 group compared to placebo. Conclusions: Supplementation with 10 or 25μg oral vitamin D3 during winter and spring for 16weeks did not significantly affect serum P1NP and serum CTX, despite increasing s-25(OH)D and decreasing PTH in a healthy immigrant population with low baseline vitamin D status.Trial registration number: NCT01263288. © 2015.

Author Keywords

CTX Bone markers immigrants Vitamin D supplementation RCT 25(OH)D P1NP

Index Keywords

immigrant investigative procedures ossification Norway double blind procedure human drug dosage form comparison osteolysis collagen type 1 procollagen type 1 amino terminal propeptide procollagen controlled study priority journal randomized controlled trial parathyroid hormone male female unclassified drug colecalciferol placebo Article intervention study adult vitamin supplementation outcome assessment normal human drug effect parathyroid hormone blood level
Link
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84929630028&doi=10.1016%2fj.bonr.2015.05.004&partnerID=40&md5=46460d5d3b40adc00ebc1f1202846194
DOI: 10.1016/j.bonr.2015.05.004
ISSN: 23521872
Cited by: 8
Original Language: English